NCT04519151View on ClinicalTrials.gov

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 12, 2021

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2029

Conditions
Ovarian NeoplasmsCarcinoma, Ovarian EpithelialNeoplasm of StomachOvarian DiseasesGenital Neoplasms, FemaleOvarian Epithelial TumorUrogenital NeoplasmsNeoplasms, Glandular and Epithelial
Interventions
DRUG

Pembrolizumab

200 mg administered by IV infusion on Day 1 of each 21-day cycle.

DRUG

Lenvatinib

20 mg administered orally (PO) QD during each 21-day cycle.

Trial Locations (1)

Unknown

RECRUITING

Sheba Medical center, Ramat Gan

All Listed Sponsors
lead

Sheba Medical Center

OTHER_GOV